Media stories about Foundation Medicine (NASDAQ:FMI) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Foundation Medicine earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.2700577392695 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Foundation Medicine (FMI) traded up $3.50 during mid-day trading on Friday, reaching $66.10. The company had a trading volume of 180,989 shares, compared to its average volume of 317,904. The firm has a market cap of $2,530.00, a PE ratio of -14.79 and a beta of -0.01. Foundation Medicine has a 1 year low of $17.10 and a 1 year high of $70.75. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million for the quarter, compared to analysts’ expectations of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm’s revenue for the quarter was up 45.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.90) EPS. equities research analysts predict that Foundation Medicine will post -4.44 earnings per share for the current year.
In related news, insider Vincent A. Miller sold 2,944 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $38.80, for a total value of $114,227.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Steven J. Kafka sold 3,201 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $38.80, for a total value of $124,198.80. The disclosure for this sale can be found here. Insiders sold a total of 85,457 shares of company stock worth $4,675,638 in the last 90 days. 2.70% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/12/24/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-foundation-medicine-fmi-stock-price.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.